Pasithea Therapeutics Corp. (KTTA) - Dilution Analysis

10-Q filing | 33.4M shares outstanding

10-K filing | 24.9M shares outstanding

POS AM filing: The Registration Statement pertains to the registration of an indeterminate amount of (i) the Registrant's common stock, (ii) the Registrant's preferred stock, (iii) warrants, (iv) subscription rights and (v) units, or any combination of the foregoing, having an aggregate offering price not to exceed $15,000,000.

8-K filing: Pasithea Therapeutics Corp. sold 14,846,665 shares of common stock and 65,153,335 pre-funded warrants in a public offering that closed on December 1, 2025, with net proceeds of approximately $54.9 million. ($60.24M proceeds)

S-1/A filing: The company is offering up to 75,000,000 shares of common stock at an assumed price of $0.80 per share, and pre-funded warrants to purchase up to 75,000,000 shares of common stock at an assumed price of $0.799 per warrant, in a reasonable best efforts offering.

S-1 filing: The company is offering shares of its common stock, pre-funded warrants, and common warrants.

10-Q filing | 7.4M shares outstanding

8-K filing: Pasithea Therapeutics Corp. sold shares of common stock and warrants in a public offering, resulting in gross proceeds of approximately $6.3 million, which includes proceeds from warrant exercises. ($5.63M proceeds)

S-1 filing: The company is offering up to 3,246,753 shares of common stock together with warrants, and pre-funded warrants to purchase up to 3,246,753 shares of common stock.

10-K filing | 2.7M shares outstanding

10-Q filing | 1.3M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 3,743,905 shares of Pasithea Therapeutics Corp. common stock by the Selling Stockholders, consisting of shares issuable upon the exercise of pre-funded warrants, Series A warrants, Series B warrants, and placement agent warrants.

8-K filing: Pasithea Therapeutics Corp. entered into a securities purchase agreement for a private placement involving pre-funded warrants and Series A and B warrants, closing on September 30, 2024, with net proceeds of approximately $4.5 million for working capital and general corporate purposes. ($0.0M proceeds)

10-Q filing | 1.0M shares outstanding

10-Q filing | 1.0M shares outstanding

10-K filing | 1.0M shares outstanding

POS AM filing: Pasithea Therapeutics Corp. is filing this post-effective amendment to deregister certain of the securities originally registered pursuant to the Registration Statement (File No. 333-271011) filed with the Securities and Exchange Commission on March 30, 2023 with respect to up to 781,302 shares of the Registrant's common stock, to be issued under the Registrant's 2021 Stock Incentive Plan.

8-K filing: Stock split 1-for-20 | Outstanding: 20,836,623 → 1,041,831

10-Q filing | 20.8M shares outstanding

8-K filing: Pasithea Therapeutics Corp. repurchased 5,323,451 shares of its common stock at a price of $0.70 per share via a tender offer, resulting in 20,819,956 shares outstanding.

10-Q filing | 26.1M shares outstanding

10-Q filing | 26.1M shares outstanding

S-3 filing: This is an S-3 filing for Pasithea Therapeutics Corp. detailing the offering of common stock for resale by selling stockholders.

10-K filing | 25.3M shares outstanding

S-3 filing: Pasithea Therapeutics Corp. may offer and sell, from time to time, up to $15,000,000 aggregate offering price of common stock, preferred stock, warrants, subscription rights or units.

8-K filing: Pasithea Therapeutics Corp. entered into a Settlement and Cooperation Agreement with the Camac Group, which includes the repurchase of 3,205,282 shares of Common Stock from the Camac Group at $1.0003 per share. ($3.21M proceeds)

10-Q filing | 26.5M shares outstanding

10-Q filing | 26.7M shares outstanding

10-Q filing | 23.0M shares outstanding

10-K filing | 22.9M shares outstanding

S-1 filing: This S-1 filing details the offering of common stock and common stock issuable upon the exercise of warrants by selling stockholders.

8-K filing: Pasithea Therapeutics Corp. sold 8,680,000 shares of common stock and warrants to purchase up to 8,680,000 shares of common stock at a combined price of $3.50 per share and associated warrant in a private placement that closed on November 29, 2021. ($30.38M proceeds)

10-Q filing | 13.2M shares outstanding

S-1/A filing: Pasithea Therapeutics Corp. is offering 2,898,551 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, in its initial public offering with an expected price between $5.00 and $7.00 per unit.

S-1/A filing: Initial public offering of up to 2,898,551 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1/A filing: Pasithea Therapeutics Corp. is offering 2,898,551 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock in an initial public offering.

S-1/A filing: Pasithea Therapeutics Corp. is offering 2,898,551 shares of common stock and warrants to purchase up to 2,898,551 shares of common stock in an initial public offering.

S-1/A filing: Pasithea Therapeutics Corp. is offering shares of its common stock in an initial public offering.

S-1/A filing: This S-1/A filing from Pasithea Therapeutics Corp. details an initial public offering of common stock, with the underwriters granted a 45-day option to purchase additional shares to cover over-allotments.

S-1 filing: This is an S-1 filing for an initial public offering of common stock. The company is offering shares of common stock and has granted the underwriters an option to purchase additional shares. The company intends to use the net proceeds of this offering for research and development, to develop its U.S. clinic and UK clinic business, and for working capital and other general corporate purposes.